Oral administration of Farnesol caused a lowering of the glycaemic peak and reduced glycaemia in streptozotocin-induced type 2 diabetic mice by inhibition of alpha-glucosidase enzyme [36], while Nerolidol displayed various bioactivities both in vitro and in vivo by showing its anti-ulcer, anti-oxidant, and anti-inflammatory properties [37], thereby indicating the anti-diabetic properties of these active compounds. This evidence concerns the gene GAA and type 2 diabetes mellitus.